# Zoledronate Early to Hip Fracture Patients - Safe and Effective?

> **NCT05025293** · PHASE4 · UNKNOWN · sponsor: **Lene Bergendal Solberg** · enrollment: 300 (estimated)

## Conditions studied

- Hip Fractures
- Osteoporosis

## Interventions

- **DRUG:** Zoledronic Acid 5Mg/Bag 100Ml Inj
- **DRUG:** sodium chloride

## Key facts

- **NCT ID:** NCT05025293
- **Lead sponsor:** Lene Bergendal Solberg
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-12-15
- **Primary completion:** 2026-03-31
- **Final completion:** 2026-03-31
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2024-04-02

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05025293

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05025293, "Zoledronate Early to Hip Fracture Patients - Safe and Effective?". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05025293. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*